Grail Inc ((GRAL)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Grail Inc.’s latest clinical study, officially titled ‘REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity,’ aims to evaluate the clinical impact of the Galleri® test, a blood-based multi-cancer early detection (MCED) test. The study seeks to enroll a diverse participant pool, with 20% from under-represented minority populations, to assess safety and test performance.
The intervention being tested is the Galleri® test, a device designed for early cancer detection through blood samples. It is intended to be used alongside usual care to improve early cancer detection rates.
The study is interventional with a non-randomized, parallel assignment model. It involves two groups: one receiving the Galleri test plus usual care, and a comparator group receiving usual care alone. There is no masking, and the primary purpose is screening.
The study began on July 12, 2024, with its primary completion and estimated completion dates yet to be determined. The last update was submitted on June 24, 2025, indicating ongoing recruitment and study progress.
This update could positively influence Grail Inc.’s stock performance by showcasing its commitment to innovation in cancer detection. As the healthcare industry increasingly focuses on early detection, Grail’s advancements may enhance investor sentiment, especially as competitors also explore similar technologies.
The study is ongoing, with further details available on the ClinicalTrials portal.